{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:49:16Z","timestamp":1789447756808,"version":"build-2803163510"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,15]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Mixed phenotype acute leukemia (MPAL) is a rare and heterogeneous type of leukemia known for its poor prognosis. The optimal treatment strategy for this condition currently lacks consensus, leaving uncertainty in its management. Nonetheless, a potential therapeutic option for patients with refractory MPAL who express target antigens is donor-derived chimeric antigen receptor T (CAR-T) cell therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We recently reported a 61-year-old woman with MPAL and elucidated its diagnosis and treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The diagnosis of MPAL was established based on the classification of World Health Organization in 2016.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Despite undergoing 3 different acute lymphoblastic leukemia (ALL) regimens and 1 acute myelogenous leukemia (AML) regimen, the patient did not achieve remission. Subsequently, the patient received human CD19-targeted CAR-T cell therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient achieved a successful and complete remission after CAR-T cell therapy. Tragically, 8 months after CAR-T infusion, the patient experienced a relapse characterized by CD19-negative disease and ultimately passed away.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case underscores the potential efficacy and safety of human-derived CD19 CAR-T cell therapy in treating refractory MPAL. While this particular patient outcome was unfortunate, it suggests that CAR-T cell therapy may still hold promise as a viable treatment option for MPAL patients unresponsive to other therapies. Further research in this field is warranted to determine the most effective treatment strategies for managing this challenging disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036397","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T21:15:23Z","timestamp":1702674923000},"page":"e36397","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Favorable response of a patient with primary B\/myeloid mixed phenotype acute Leukemia to CD19-CAR-T: Case report and literature review"],"prefix":"10.1097","volume":"102","author":[{"given":"Lixin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Pang","sequence":"additional","affiliation":[{"name":"Shenzhen Hospital of Southern Medical University\/Shenzhen Clinical Medical school, Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuling","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqiao","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Shenzhen Haoshi Biotechnology Co., Ltd, Shenzhen, China"},{"name":"Shenzhen University \u2013 Haoshi Cell Therapy Institute, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Li","sequence":"additional","affiliation":[{"name":"Shenzhen Haoshi Biotechnology Co., Ltd, Shenzhen, China"},{"name":"Shenzhen University \u2013 Haoshi Cell Therapy Institute, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Tang","sequence":"additional","affiliation":[{"name":"Shenzhen Haoshi Biotechnology Co., Ltd, Shenzhen, China"},{"name":"Shenzhen University \u2013 Haoshi Cell Therapy Institute, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China"},{"name":"Shenzhen University \u2013 Haoshi Cell Therapy Institute, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/leu.2010.119","article-title":"Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification.","volume":"24","author":"van den Ancker","year":"2010","journal-title":"Leukemia"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/leu.2010.202","article-title":"Mixed-phenotype acute leukemia: historical overview and a new definition.","volume":"24","author":"Weinberg","year":"2010","journal-title":"Leukemia"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2012.064485","article-title":"Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification.","volume":"97","author":"Yan","year":"2012","journal-title":"Haematologica"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/s41375-018-0058-4","article-title":"Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis.","volume":"32","author":"Maruffi","year":"2018","journal-title":"Leukemia"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","article-title":"Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification.","volume":"117","author":"Matutes","year":"2011","journal-title":"Blood"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.leukres.2015.03.012","article-title":"Survival of patients with mixed phenotype acute leukemias: a large population-based study.","volume":"39","author":"Shi","year":"2015","journal-title":"Leuk Res"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00277-020-04354-2","article-title":"Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.","volume":"100","author":"Rasekh","year":"2021","journal-title":"Ann Hematol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-018-04924-z","article-title":"Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.","volume":"9","author":"Takahashi","year":"2018","journal-title":"Nat Commun"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/bloodadvances.2019033076","article-title":"PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation Blood Adv 2018;2(23):3526-3539.","volume":"3","author":"Xiao","year":"2019","journal-title":"Blood Adv"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","article-title":"The genetic basis and cell of origin of mixed phenotype acute leukaemia.","volume":"562","author":"Alexander","year":"2018","journal-title":"Nature"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:13:31Z","timestamp":1746321211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":10,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036397","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]}}}